Prescribing Agreement for ED and Dysmenorrhea Products
Filed with ASX · · 2 pages · English
EVE Health Group Limited on 6ix
Earlier from EVE Health
- EVE Completes Nextract Acquisition
- Results of Meeting
- Notice of General Meeting/Proxy Form
- Reinstatement to Quotation
- EVE to Acquire Nextract, Expanding into $5.3B ED Market
Later from EVE Health
- EVE Submits First Commercial Purchase Order for Dyspro
- Aust Regulatory Path Cleared for ED & Dysmenorrhea Products
- Appendix 4E
- Appointment of Dr Fiona Cousins to Scientific Advisory Board
- Eve Commences Distribution of Dyspro
Follow EVE Health into a list and get an email when it puts out news.
Follow EVE Health